JP2017524031A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524031A5
JP2017524031A5 JP2017521620A JP2017521620A JP2017524031A5 JP 2017524031 A5 JP2017524031 A5 JP 2017524031A5 JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017524031 A5 JP2017524031 A5 JP 2017524031A5
Authority
JP
Japan
Prior art keywords
cells
subject
gamma delta
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017521620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524031A (ja
Filing date
Publication date
Priority claimed from GB201412175A external-priority patent/GB201412175D0/en
Priority claimed from GB201415379A external-priority patent/GB201415379D0/en
Priority claimed from GBGB1506423.1A external-priority patent/GB201506423D0/en
Application filed filed Critical
Priority claimed from PCT/GB2015/051985 external-priority patent/WO2016005752A1/en
Publication of JP2017524031A publication Critical patent/JP2017524031A/ja
Publication of JP2017524031A5 publication Critical patent/JP2017524031A5/ja
Pending legal-status Critical Current

Links

JP2017521620A 2014-07-09 2015-07-08 ガンマデルタｔ細胞およびその使用 Pending JP2017524031A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1412175.0 2014-07-09
GB201412175A GB201412175D0 (en) 2014-07-09 2014-07-09 Gamma T cells and uses thereof
GB1415379.5 2014-08-29
GB201415379A GB201415379D0 (en) 2014-08-29 2014-08-29 Gamma T cells and uses thereof
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof
GB1506423.1 2015-04-15
PCT/GB2015/051985 WO2016005752A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020115432A Division JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2017524031A JP2017524031A (ja) 2017-08-24
JP2017524031A5 true JP2017524031A5 (2) 2018-08-16

Family

ID=53776892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017521620A Pending JP2017524031A (ja) 2014-07-09 2015-07-08 ガンマデルタｔ細胞およびその使用
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタｔ細胞およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタｔ細胞およびその使用

Country Status (12)

Country Link
US (2) US20170196910A1 (2)
EP (1) EP3167050A1 (2)
JP (3) JP2017524031A (2)
KR (1) KR20170045205A (2)
CN (1) CN107075480A (2)
AU (1) AU2015287456A1 (2)
BR (1) BR112017000464A2 (2)
CA (1) CA2954546A1 (2)
EA (1) EA201790010A1 (2)
IL (1) IL249970B (2)
SG (1) SG11201700134PA (2)
WO (1) WO2016005752A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
WO2016023491A1 (en) * 2014-08-12 2016-02-18 The University Of Hong Kong Biophosphonate compounds and gamma delta t cell-mediated therapy for treating epstein-barr virus-associated disorders
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
US20180028566A1 (en) * 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
EP3516043A1 (en) * 2016-09-26 2019-07-31 Tessa Therapeutics Pte. Ltd. T cell expansion method
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
CA3114292A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
SG11202103234RA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS
US20210388100A1 (en) 2018-10-01 2021-12-16 Adicet Bio, Inc. Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of hematological tumors
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
EP4183871A1 (en) 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
KR20240149401A (ko) 2022-02-16 2024-10-14 프리오테라 에스에이에스 S1p 수용체 조정제와 조합된 car 세포를 이용한 치료 방법
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
WO2025046256A1 (en) 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147186A4 (en) * 1999-01-28 2002-05-15 Palmetto Health Alliance D B A In vitro activated gamma delta lymphocytes
ES2336302T3 (es) * 2000-04-03 2010-04-12 Therapure Biopharma Inc. Produccion de celulas ttcr gamma delta.
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
DE602005022728D1 (de) * 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
EP1930414B1 (en) 2005-09-08 2012-07-18 Medinet Co., Ltd. Method for activation treatment of antigen-presenting cell
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Similar Documents

Publication Publication Date Title
JP2017524031A5 (2)
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
BR112017020750A2 (pt) células t modificadas e métodos de produção e utilização das mesmas
HK1203489A1 (en) Purinone compounds as kinase inhibitors
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
WO2017069958A3 (en) Modulation of novel immune checkpoint targets
WO2014153115A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP4353254A3 (en) Methods for treating skin infection by administering an il-4r antagonist
WO2018005521A3 (en) Cell culture chambers and methods of use thereof
MX2016014548A (es) Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa.
CO2018012506A2 (es) Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
FR2958163B1 (fr) Preparation issue d'une culture in vitro de cellules dedifferencieres non elicitees d'arganier, leur utilisation pour le traitement du vieillissement cutane, de l'inflammation et de la cicatrisation, et leur obtention.
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
WO2016048861A3 (en) Heterocyclic compounds and use thereof
EA201692550A1 (ru) Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
Goudarzi et al. Prevalence of blaCTX-M gene in multi-resistant Escherichia coli isolated from Urinary Tract Infections, Tehran, Iran